Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
PaperCitations, authors & open-access status
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 59 citations, 2024 year and hybrid oa status.
59
Citations
2024
Year
hybrid
OA Status